PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Access to medicine after Brexit: Lords ask Minister for clarity

The House of Lords EU Home Affairs Sub-Committee has today written to Matt Hancock MP, Secretary of State for Health and Social Care (DHSC) asking for clarity on the Government’s contingency preparations to ensure the UK has continued access to medicines and medical products in the event of a ‘no deal’ Brexit.
The letter follows an evidence session the Committee held with witnesses from Nuffield Trust, British Association of European Pharmaceutical Distributors and evidence given by officials from DHSC during a private briefing.
The evidence received suggests there is still concern that a no deal Brexit may limit the availability of medicines and medical products in the UK and that there was little sign to date of potential delays on the border being addressed.
The Government’s current guidance is to stockpile six weeks’ worth of medicines and medical products in the event of blockages at borders, however medicines with short shelf lives cannot be stockpiled and would have to be flown in.
In the letter the Committee ask the Government what consideration they have taken ito the expense of flying in medical supplies for a six week period and what work has been undertaken to ensure the import of medicines and medical products is treated as a priority at the border in the event of no deal.
The Committee have also asked for answers in other areas including:
  • How confident are you that the contingency measures deployed as an immediate response to secure the supply of medicines and medical products can be sustained beyond the first six weeks after Brexit, should this be required?
  • Can you provide more detail on the tender for additional storage capacity, including: the amount of funding awarded; the size of the storage obtained; and how much of that is for refrigerated storage.
  • What plans has the Government made to secure and prioritise airborne routes for medical products?
  • What are the Government’s plans to encourage drug companies to prioritise introducing new products to market in the UK?

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026